immunomodulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
== Demographics and geographical distribution == Bektashis are mainly found throughout Anatolia, the Balkans and among Ottoman-era Greek Muslim communities. According to a 2005 estimate by Dedebaba Reshat Bardhi, there are over seven million Bektashis worldwide, though more recent studies put the figure as high as 20 million. According to Albania's latest census in September 2023, Bekhtashis number slightly make up 9% of the Muslim population and 5% of the country's population. An additional 12.5 million Bektashis are estimated to live in Turkey. The term Alevi–Bektashi is used frequently in current Turkish religious discourse as an umbrella term for Alevism and Bektashism, despite their distinct origins and separate belief systems. Alevi/Bektashi is officially recognized through Ministry of Culture and Tourism under the 'Presidency of Alevi/Bektashi Culture'. There are also important Bektashi communities among the Albanian communities of North Macedonia and Kosovo, the most important being the Arabati Baba Teḱe in the city of Tetovo, which was until recently under the guidance of Baba Tahir Emini (1941–2006). Following the death of Baba Tahir Emini, the dedelik of Tirana appointed Baba Edmond Brahimaj (known as Baba Mondi), formerly head of the Turan Tekke of Korçë, to oversee the Harabati baba tekke. A splinter branch of the order has recently sprung up in the North Macedonian town of Kičevo which has ties to the Turkish Bektashi community under Haydar Ercan Dede rather than the order's headquarters in Tirana.
Whatever moral and religious interpretation one places upon it, the fall in Lynn clearly marked a turning point in [Eddy's] life, the moment when she began to take charge of her life... She herself consistently, and with increasing fervor and conviction, attributed that change to a new understanding of God's relation to the world, and to a new sense of her own special divine mission. Whether we label this delusion or revelation, the fact remains that the woman was fundamentally empowered, and that there was no external, material change to account for that increase of power.
=== 2. CAL vs. Gingival Enlargement === While CAL represents true periodontal destruction, gingival enlargement refers to an increase in the size of the gingival tissues, which may or may not be associated with attachment loss. In CAL, the gingival margin often migrates apically, leading to gingival recession and increased CEJ–JE distance. The probing depth increases due to a combination of attachment loss and bone loss, and the CEJ is usually clinically visible. Gingival enlargement, on the other hand, usually results in a false pocket, as the gingival margin moves coronally and covers the CEJ. The probing depth increases due to tissue overgrowth rather than periodontal attachment loss. Attachment and bone loss are typically absent unless gingival enlargement coexists with periodontitis. The pathogenesis of gingival enlargement varies depending on the underlying cause. Inflammatory gingival enlargement is commonly associated with plaque, calculus, ill-fitting restorations, orthodontic appliances, or fractured teeth. The gingiva may appear red or bluish, soft, friable, and may become firm if the condition becomes chronic. Drug-induced gingival enlargement is commonly associated with anticonvulsants such as phenytoin, immunosuppressants like cyclosporine, and calcium channel blockers such as nifedipine. These cases typically present as firm, pink, bead-like gingiva, often more prominent in the anterior regions.
Sources: en.wikipedia.org
I would guess if we had gone in there, we would still have forces in Baghdad today. We'd be running the country. We would not have been able to get everybody out and bring everybody home. And the final point that I think needs to be made is this question of casualties. I don't think you could have done all of that without significant additional US casualties, and while everybody was tremendously impressed with the low cost of the conflict, for the 146 Americans who were killed in action and for their families, it wasn't a cheap war.
=== Bi–Bo === Klaus Biemann (1926–2016). Austrian chemist at MIT, the "father of organic mass spectrometry" and particularly noted for his role in advancing protein sequencing with tandem mass spectrometry. Member Natl. Acad. Sci. USA. Ethel Ronzoni Bishop (1890–1975). American biochemist and physiologist at Washington University in St. Louis who studied carbohydrate metabolism. Pamela J. Bjorkman (b. 1956). American biochemist at Caltech, who studies immune recognition of viral pathogens. Member Natl. Acad. Sci. USA. Elizabeth Blackburn AC FRS FAA FRSN (b. 1948). Australian-American biochemist, Nobel Laureate, co-discoverer of telomerase. Konrad Emil Bloch FRS (1912–2000). German-American biochemist at Harvard, who worked on the mechanism and regulation of cholesterol and fatty acid metabolism. Nobel Prize in Physiology or Medicine 1964. Elkan Blout (1919–2006). American biochemist at Harvard, who worked on peptide structure and conformation, including cyclic peptides. Member Natl. Acad. Sci. USA. David Mervyn Blow FRS (1931–2004). British X-ray crystallographer at Imperial College London, who worked on protein structure. Tom Blundell, FRS (b. 1942). British biochemist at the University of Cambridge, structural biologist, and science administrator. Aaron Bodansky (1887–1960). Russian-born American biochemist at the Hospital for Joint Diseases, New York, specializing in the area of calcium metabolism. Paul D. Boyer (1918–2018). American biochemist, at UCLA who studied ATP synthase. Nobel Prize in Chemistry in 1997. Member Natl. Acad. Sci. USA.
=== Satiety effects === In 2001, it was reported that in a human study examining the usefulness of CNTF for treatment of motor neuron disease, CNTF produced an unexpected and substantial weight loss in the study subjects. Further investigation revealed that CNTF could reduce food intake without causing hunger or stress, making it a candidate for weight control in leptin-resistant subjects, as CNTF is believed to operate like leptin, but by a non-leptin pathway.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.